Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)

Benedetta Pellegrino, Antonino Musolino, Olga Serra et al.|Journal for ImmunoTherapy of Cancer|2023

Cited by 10